JUN 11, 2015 7:00 AM PDT

The dynamics of β-amyloid plaque genesis - an in vivo study in transgenic mice of Alzheimer's disease

Sponsored by: Andor, Andor
Speakers
  • Postdoctoral Researcher, German Center for Neurodegenerative Diseases
    Biography
      Steffen Burgold is a postdoctoral researcher with a strong focus on imaging technology and its applications at the department for translational brain research (Prof. Dr. Jochen Herms) of the German Center for Neurodegenerative diseases (DZNE) in Munich, Germany. He studied biotechnology in Jena and photonics in Berlin and gained research experience in both biotech industry (Novosom AG, Halle/Saale) as well as academia (Charité, Berlin). His PhD degree in neurobiology Mr. Burgold earned from the Ludwig-Maximilians-University Munich where he applied his biological and technical knowledge in biomedical research of neurodegeneration. During his PhD studies he established a workflow to study the growth kinetics and genesis of β-amyloid plaques in the laboratory of Prof. Dr. Jochen Herms by applying long-term in vivo two-photon microscopy in combination with advanced image analysis procedures. This work resulted in several first authorships and is currently applied in preclinical studies to investigate the efficacy of therapeutic strategies to treat Alzheimer's disease.
    • Research Assistant, German Center for Neurodegenerative Diseases
      Biography
        Finn Peters is a German Biochemist with a strong focus on neuroscience and neurodegenerative diseases. He received his education at the University of Hamburg, the Paris Diderot University and the Free University of Berlin. After graduation he continued his training as a research assistant at the Max Planck Institute for Medical Research in Heidelberg until he joined the laboratory of Professor Jochen Herms at the Bur in Munich. Currently, Finn Peters applies chronic in vivo two-photon microscopy to investigate the pathological mechanisms underlying Alzheimer´s disease. For this purpose he uses Imaris-assisted three-dimensional reconstruction of amyloid-beta plaques by surface rendering and develops Matlab-assisted routines for the semi-automatic quantification. This work facilitates the precision and evaluation time to assess the in vivo potency of novel drug candidates for the potential treatment of Alzheimer´s disease.

      Abstract:
      Date: Thursday, June 11th, 2015
      Time: 07:00AM PDT, 10:00AM EDT, 03:00PM BST

      Alzheimer's disease (AD) is the most common form of dementia with nearly 44 million people affected worldwide. Characteristic neuropathological hallmarks of the disease are β-amyloid plaques which result from abnormal protein aggregation and deposition of β-amyloid peptide (Aβ). Aβ is produced by cleavage of the amyloid precursor protein. The amyloid-cascade-hypothesis postulates, based on strong genetic evidences, that Aβ accumulation is the central event in the etiology of AD. Here we use long-term in vivo two-photon imaging to investigate the dynamics of β-amyloid plaque genesis and growth in transgenic mouse models of Alzheimer's disease. A fluorescent dye is used to stain β-amyloid plaques in vivo and repeated injections enable us to follow plaque formation as well as their growth kinetics. In order to assess the size of β-amyloid plaques over time we established image analysis protocols to extract quantitative data from the high resolution four dimensional datasets. The results from our study in mice showed sigmoid-shaped growth kinetics similar to those found in humans with a familiar record of Alzheimer's disease by applying a β-amyloid radioactive tracer in combination with positron emission tomography imaging. We hope this work will help testing therapeutic strategies for Alzheimer's disease in animal models and translating them to the human situation.


      Who Should Attend?
      - Everybody interested in recent developments in Alzheimer's disease therapy
      - Researchers working in the field of β-amyloid plaque genesis and growth
      - Scientists interested in new methods of testing efficacy of Alzheimer's therapies in preclinical studies


      Key Learning Objectives:
      - Methods to investigate the efficacy of therapeutic strategies to treat Alzheimer's disease.

      Show Resources
      You May Also Like
      OCT 02, 2019 11:00 AM PDT
      OCT 02, 2019 11:00 AM PDT
      DATE: October 2, 2019TIME: 11:00am PDT, 2:00pm EDT Ditch the Excel spreadsheets and manage your molecular workflows entirely in your LIMS Achieve configuration of molecular workf...
      JAN 23, 2020 9:00 AM PST
      C.E. CREDITS
      JAN 23, 2020 9:00 AM PST
      DATE: January 23, 2020 TIME: 9:00am PST, 12:00pm EST...
      SEP 05, 2019 4:00 PM CEST
      C.E. CREDITS
      SEP 05, 2019 4:00 PM CEST
      DATE: September 5, 2019TIME: 7:00am PT, 10:00am ET, 4:00pm CEST PCR (Polymerase Chain Reaction) has gone through a massive evolution since its development in 1983. Besides it...
      AUG 27, 2019 9:00 AM PDT
      C.E. CREDITS
      AUG 27, 2019 9:00 AM PDT
      DATE: August 27, 2019 TIME: 9:00am PDT, 12:00pm EDT Immunotherapies targeting PD-1 or PD-L1 have proven remarkably effective for treating cancer in some patients, with considerabl...
      FEB 26, 2020 9:00 AM PST
      Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
      C.E. CREDITS
      FEB 26, 2020 9:00 AM PST
      Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
      DATE: February 26, 2020 TIME: 9:00am PST 3D cell culture and analysis and the study of organoids and spheroids are becoming more prevalent as a research method in publications as traditional...
      NOV 18, 2019 7:00 AM PST
      C.E. CREDITS
      NOV 18, 2019 7:00 AM PST
      DATE: November 18, 2019TIME: 7:00am PST, 11:00am EST, 4:00pm CEWT How often do you pipette in your cell culture lab every day? Usually, we do it so often that we tend stop th...
      Loading Comments...
      Show Resources